• Corpus ID: 80409716

Évaluation de la mesure de la graisse viscérale abdominale dans les rhumatismes inflammatoires chroniques (polyarthrite rhumatoïde et spondyloarthropathies)

  title={{\'E}valuation de la mesure de la graisse visc{\'e}rale abdominale dans les rhumatismes inflammatoires chroniques (polyarthrite rhumato{\"i}de et spondyloarthropathies)},
  author={Camille Souffir},
Les rhumatismes inflammatoires comme la polyarthrite rhumatoide (PR) et les spondyloarthropathies (SpA) sont associes a une augmentation du risque cardiovasculaire (CV). La graisse viscerale abdominale (VAT) est un facteur de risque CV independants des autres facteurs de risque. L’objectif de ce travail est d’evaluer l’interet de la mesure de VAT au cours des rhumatismes inflammatoires : etude des facteurs associes a son exces et variations au cours du suivi. Deux etudes mesurant la VAT par… 


Le tissu adipeux : un véritable organe endocrine
L'activite augmentee de la 11β-hydroxysteroide deshydrogenase de type 1 dans le tissu gras visceral contribue tres activement a la presence of hautes concentrations of cortisol dans ce tissu, participant ainsi a the distribution of the graisse de l'organisme et aux risques cardiovasculaires.
Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis.
There is little doubt that physicians caring for patients with SpA should aim at controlling both inflammation and traditional cardiovascular risk factors, and an integrated approach is expected to benefit patients in multiple levels.
Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study
Rigorous application of systematic evaluation of comorbidities may permit earlier detection of previously unknown risk factors, which may ultimately result in an improved outcome of patients with SpA.
Cardiovascular events in ankylosing spondylitis: an updated meta-analysis.
Cardiovascular and Cerebrovascular Diseases in Ankylosing Spondylitis: Current Insights
CV risk management appears necessary for ankylosing spondylitis patients, and this should consist of assessment and treatment of the “traditional” CV risk factors, and, on the other hand, effective suppression of the inflammatory process.
High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity.
The association of AS disease activity with MetS suggests that CVD in AS patients may, at least in part, be attributed to the inflammatory burden of the disease.
High prevalence of metabolic syndrome in patients with ankylosing spondylitis
This preliminary report points out a higher prevalence of MetS in AS pts than in controls, and no significant relationship emerged in MetS prevalence among AS pts regarding the mean value of age, disease duration, Bath Ankylosing Spondylitis Functional Index, and the Italian version of Health Assessment Questionnaire.
Mortality in spondylarthritis.
Radiographic progression is associated with increased cardiovascular risk in patients with axial spondyloarthritis
The Framingham risk score (FRS) was higher in axSpA patients than in a matched general population and radiographic progression in the spine was associated with a high estimated 10-year CVD risk.
Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables
A significant prevalence of hyperhomocysteinemia is found in Mexican patients with AS mainly associated to a worst functional impairment and further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients.